Sonus, OncoGenex Merge Into Specialty Oncology Company
Combined company will have three drugs in clinical development, including lead candidate OGX-011 in Phase II for prostate cancer.
Combined company will have three drugs in clinical development, including lead candidate OGX-011 in Phase II for prostate cancer.